CA
Therapeutic Areas
Modulight Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| eOPN3‑Trigeminal Neuropathic Pain | Trigeminal Neuropathic Pain | Preclinical |
| eOPN3‑Movement Disorders | Movement Disorders (Parkinson's, Essential Tremor) | Preclinical |
| eOPN3‑Drug‑Resistant Epilepsy | Drug‑Resistant Epilepsy | Preclinical |
Leadership Team at Modulight Bio
OL
Ofir Levi, PhD
Co‑Founder and Chairman of the Board
YE
Yotam Eldar, MD
Co‑Founder and Chief Executive Officer
OY
Ofer Yizhar, PhD
Scientific Co‑Founder and Chief Scientific Officer
YK
Yoav Kfir, PhD
VP of Research and Development
SD
Sasha Devore, PhD
Director of Scientific Communications and Engagement
NS
Noam Shuv, MD
Chief of Staff
ZS
Ziv Spada
Director of Operations
TS
Tamar Shai Granot
Director of Product
ES
Evyatar Swissa, PhD
Director of In‑vivo Research
DK
Dahlia Kushinsky, PhD
Scientific Director of Collaborative Research